For instance, a bispecific antibody targeting both PD‐1 and TIGIT is currently being assessed in a phase II clinical trial for its efficacy and safety in the perioperative treatment of HER2‐positive, unresectable locally advanced GC in combination with trastuzumab and chemotherapy (NCT06630130). This evidence concerns the gene PDCD1 and gastric cancer.